Cite
HARVARD Citation
Khoo, S. et al. (2021). Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. Journal of antimicrobial chemotherapy. pp. 3286-3295. [Online].